184 related articles for article (PubMed ID: 20388222)
1. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Mahner S; Woelber L; Eulenburg C; Schwarz J; Carney W; Jaenicke F; Milde-Langosch K; Mueller V
BMC Cancer; 2010 Apr; 10():139. PubMed ID: 20388222
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
[TBL] [Abstract][Full Text] [Related]
3. Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Christensen RK; Bartels A; Brünner N; Jakobsen A
BMC Cancer; 2010 May; 10():185. PubMed ID: 20459644
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
6. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
Kozłowski M; Laudański W; Mroczko B; Szmitkowski M; Milewski R; Łapuć G
Adv Med Sci; 2013; 58(2):227-34. PubMed ID: 23773968
[TBL] [Abstract][Full Text] [Related]
7. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer.
Chaudhry P; Srinivasan R; Patel FD; Gopalan S; Majumdar S
Int J Cancer; 2008 Apr; 122(8):1716-21. PubMed ID: 18092329
[TBL] [Abstract][Full Text] [Related]
9. Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
Yoon HI; Koom WS; Kim YB; Min BS; Lee KY; Kim NK; Shin SJ; Ahn JB; Keum KC
J Cancer Res Clin Oncol; 2014 Mar; 140(3):399-409. PubMed ID: 24390211
[TBL] [Abstract][Full Text] [Related]
10. Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?
Le T; Faught W; Hopkins L; Fung-Kee-Fung M
J Obstet Gynaecol Can; 2009 Jan; 31(1):42-7. PubMed ID: 19208282
[TBL] [Abstract][Full Text] [Related]
11. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
[TBL] [Abstract][Full Text] [Related]
12. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
14. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Apr; 117(1):109-16. PubMed ID: 20056267
[TBL] [Abstract][Full Text] [Related]
15. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.
Karihtala P; Mäenpää J; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2010 Mar; 30(3):1001-6. PubMed ID: 20393027
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract][Full Text] [Related]
18. Serum markers in early-stage and locally advanced melanoma.
Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
[TBL] [Abstract][Full Text] [Related]
19. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
20. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]